TriSalus Life Sciences (TLSI) Total Current Liabilities (2021 - 2026)

TriSalus Life Sciences' Total Current Liabilities history runs 6 years deep, the most recent figure standing at $11.8 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities changed 0.28% year-over-year to $11.8 million in Q1 2026; TTM through Mar 2026 was $11.8 million, a 0.28% change from a year earlier, with the FY2025 full-year figure at $11.5 million, up 12.43% from the prior year.
• Total Current Liabilities climbed to $11.8 million in Q1 2026 per TLSI's latest filing, from $11.5 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $32.4 million in Q4 2022 and bottomed at $1.7 million in Q2 2022.
• The 5-year median for Total Current Liabilities is $10.2 million (2024), against an average of $10.3 million.
• Across the five-year window, Total Current Liabilities jumped 1920.27% in 2022 and slumped 54.61% in 2023, its largest moves.
• Year by year, Total Current Liabilities stood at $32.4 million in 2022, then slumped by 54.61% to $14.7 million in 2023, then sank by 30.36% to $10.2 million in 2024, then climbed by 12.43% to $11.5 million in 2025, then climbed by 2.5% to $11.8 million in 2026.
• Per Business Quant, the three latest TLSI Total Current Liabilities figures stand at $11.8 million (Q1 2026), $11.5 million (Q4 2025), and $10.9 million (Q3 2025).